share_log

中智藥業(03737.HK)斥300萬美元認購美資GABAeron優先股

ZHONGZHIPHARM (03737.HK) invests 3 million USD to subscribe to the preferred shares of the US company GABAeron.

AASTOCKS ·  Dec 23 22:13

ZHONGZHIPHARM (03737.HK) announced that it has signed an investment agreement with the USA Biomedical company GABAeron. According to this, the group will invest 3 million USD to subscribe to 3 million shares of GABAeron's Series A preferred stock, accounting for approximately 11.5% of its preferred stock. This investment will support the advancement of GABAeron's GR01 cell transplantation clinical trial for the treatment of Alzheimer's disease.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment